Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

The Use Pattern and Clinical Impact of Novel P2Y12 Receptor Antagonists for Acute Myocardial Infarction in Korea

  • Kim, Soo-Joong (Division of Cardiology, Department of Internal Medicine, Kyung Hee University Medical Center, Kyung Hee University College of Medicine)
  • Received : 2017.09.27
  • Accepted : 2017.11.08
  • Published : 2017.11.30
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. https://doi.org/10.1056/NEJMoa010746
  2. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15. https://doi.org/10.1056/NEJMoa0706482
  3. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57. https://doi.org/10.1056/NEJMoa0904327
  4. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;130:e344-426.
  5. Green A, Pottegard A, Broe A, et al. Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction: a Danish nationwide population-based cohort study. BMJ Open 2016;6:e010880. https://doi.org/10.1136/bmjopen-2015-010880
  6. Yudi MB, Clark DJ, Farouque O, et al. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Intern Med J 2016;46:559-65. https://doi.org/10.1111/imj.13041
  7. Angeras O, Hasvold P, Thuresson M, Deleskog A, OBraun O. Treatment pattern of contemporary dual antiplatelet therapies after acute coronary syndrome: a Swedish nationwide population-based cohort study. Scand Cardiovasc J 2016;50:99-107. https://doi.org/10.3109/14017431.2015.1119304
  8. Sheikh Rezaei S, Geroldinger A, Heinze G, Reichardt B, Wolzt M. Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: a nationwide long-term registry analysis from 2009 to 2014. Int J Cardiol 2017;235:61-6. https://doi.org/10.1016/j.ijcard.2017.02.096
  9. Larmore C, Effron MB, Molife C, et al. "Real-world" comparison of prasugrel with ticagrelor in patients with acute coronary syndrome treated with percutaneous coronary intervention in the United States. Catheter Cardiovasc Interv 2016;88:535-44. https://doi.org/10.1002/ccd.26279
  10. Kim C, Shin DH, Ahn CM, et al. The use pattern and clinical impact of new antiplatelet agents including prasugrel and ticagrelor on 30-day outcomes after acute myocardial infarction in Korea: Korean Health Insurance Review and Assessment data. Korean Circ J. Korean Circ J 2017;47:877-87. https://doi.org/10.4070/kcj.2017.0146